Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Self-Expanding TAVR in Patients With Aortoventricular Angulation.
Popma JJ, Reardon MJ, Yakubov SJ, Hermiller JB Jr, Harrison JK, Gleason TG, Conte JV, Deeb GM, Chetcuti S, Oh JK, Boulware MJ, Huang J, Adams DH; CoreValve US Clinical Investigators. Popma JJ, et al. JACC Cardiovasc Imaging. 2016 Aug;9(8):973-81. doi: 10.1016/j.jcmg.2016.06.002. JACC Cardiovasc Imaging. 2016. PMID: 27491485 Free article. Clinical Trial.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. Stone GW, et al. Among authors: popma jj. N Engl J Med. 2004 Jan 15;350(3):221-31. doi: 10.1056/NEJMoa032441. N Engl J Med. 2004. PMID: 14724301 Free article. Clinical Trial.
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. Stone GW, et al. Among authors: popma jj. Circulation. 2004 Apr 27;109(16):1942-7. doi: 10.1161/01.CIR.0000127110.49192.72. Epub 2004 Apr 12. Circulation. 2004. PMID: 15078803 Clinical Trial.
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C; FilterWire EX Randomized Evalulation (FIRE) Investigators. Jonas M, et al. Among authors: popma jj. Eur Heart J. 2006 Apr;27(8):920-8. doi: 10.1093/eurheartj/ehi736. Epub 2006 Jan 16. Eur Heart J. 2006. PMID: 16415300 Clinical Trial.
Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial.
Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, Stone GW. Halkin A, et al. Among authors: popma jj. Am Heart J. 2006 Apr;151(4):915.e1-7. doi: 10.1016/j.ahj.2005.09.018. Am Heart J. 2006. PMID: 16569562 Clinical Trial.
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ; TAXUS-IV Investigators. Pinto DS, et al. Among authors: popma jj. J Am Coll Cardiol. 2006 Jul 4;48(1):32-6. doi: 10.1016/j.jacc.2006.02.060. Epub 2006 Jun 9. J Am Coll Cardiol. 2006. PMID: 16814645 Free article. Clinical Trial.
Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Kirtane AJ, et al. Among authors: popma jj. JACC Cardiovasc Interv. 2009 Oct;2(10):967-76. doi: 10.1016/j.jcin.2009.08.008. JACC Cardiovasc Interv. 2009. PMID: 19850257 Free article. Clinical Trial.
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ; ENDEAVOR IV Investigators. Leon MB, et al. Among authors: popma jj. JACC Cardiovasc Interv. 2009 Dec;2(12):1208-18. doi: 10.1016/j.jcin.2009.10.008. JACC Cardiovasc Interv. 2009. PMID: 20129547 Free article. Clinical Trial.
576 results